Prenosis announces partnership to fight hospital sepsis with precision diagnostics


The partnership will support efforts to build the NOSIS ™ record for sepsis treatment and the steps towards FDA approval of the Prenosis Sepsis Immunoscore ™. to advance

Released: October 13, 2021 at 9:00 AM MDT|Updated: 1 hour ago

CHICAGO, Oct 13, 2021 / PRNewswire / – Prenosis, Inc., a precision diagnostics company that transforms clinical diagnosis with predictive intelligence, today announced the expansion of an existing partnership with Roche Diagnostics, which will include almost $ 6M improve and accelerate the clinical detection of sepsis through advanced precision diagnostics. Building on the collaboration that the companies started together in 2020, Prenosis will become its core area of ​​NOSIS. expand significantly Record, and the two companies will work together to obtain FDA approval for the Prenosis Sepsis Immunoscoreand Roche Elecsys® IL-6 assay. These tools are designed to provide physicians with powerful new solutions to combat sepsis through early risk detection.


The Prenosis dataset, which includes Elecsys IL-6 measurements, in addition to measurements of various parameters representing different dimensions of the immune response, is the world’s largest and fastest growing hybrid biomarker clinical dataset for sepsis treatment. The partnership advances the unique combination of a traditional diagnostic test with next-generation predictive analytics, demonstrating the potential to usher in a new era of holistic digital diagnostics for broader profiling of complex, heterogeneous hospital conditions.

According to the World Health Organization, more than 11 million people die of sepsis each year worldwide, more than the number of deaths from all cancers combined. Studies show that sepsis is the leading cause of death in US hospitals, taking the total annual costs of treatment and rehabilitation up. to be appreciated $ 62 billion.1 Before the COVID-19 pandemic, at least 1.7 million adults in The United States developed sepsis annually. During the pandemic, this problem was greatly exacerbated as most COVID-19 deaths are due to viral and / or bacterial sepsis.2

Predicting patients at risk early on who will need an emergency room exam and hospitalization can dramatically improve outcomes. Combining routine clinical information with additional critical biomarkers could help identify at-risk patients earlier and more accurately for life-saving treatment.

Roche Elecsys® The IL-6 test measures interleukin-6 concentrations from plasma or serum samples from patients. Elecsys IL-6 is a predictive biomarker that is essential in the pathways of many inflammatory diseases, including sepsis, due to its early elevation. The Elecsys IL6 results can be provided in 18 minutes. The prenosis-sepsis immune scoreDiagnostic uses the combination of Elecsys IL-6 with other sepsis biomarkers and various clinical risk parameters and aims to predict, diagnose and treat sepsis earlier.

“We are excited to expand our relationship with Roche and accelerate the birth of ‘prenostic’ testing to ease the burden of the sepsis crisis,” said Prenosis CEO and Co-Founder Bobby reddy jr. “Prenostics or predictive and precise diagnostics tests the right patient parameters at the right time for the right clinical situation / the right context. The prenosis platform heralds a new era in preventive diagnostics. The implications are groundbreaking: we have the ability to predict diseases much earlier, accurately and cost-effectively, which enables prevention rather than treatment. “

The Sepsis ImmunoScoreis an Artificial Intelligence / Machine Learning (AI / ML) software as a Medical Device (SaMD) that Prenosis plans to submit to the FDA for approval by the end of the year. It is designed to help assess the risk of progression to sepsis in patients admitted to the emergency room or hospital. The solution includes holistic, multi-dimensional inputs using machine learning to more appropriately capture the vast heterogeneity of sepsis and improve the accuracy of the diagnosis compared to current standard of care risk assessments. The solution includes 23 parameters from the patient’s hospital electronic medical record (EMR) including demographics, vital signs, laboratory values ​​and other specific sepsis biomarkers, including Elecsys IL-6.

The diagnosis creates a calculated sepsis risk score, a risk stratification category and other supplementary information that can be visualized in a unique sepsis patient view within a hospital electronic medical record or via a web interface. By using parameters that represent many dimensions of information, the Sepsis ImmunoScoreThe aim is to diagnose sepsis more effectively and to stratify patients for care according to the severity of the disease.

About prenosis
Prenosis is a health technology innovator aiming to usher in a new era of precision diagnostics in acute care with artificial intelligence. Its immunixThe precision diagnostic platform uses machine learning algorithms that have been trained on deep biological data and broad clinical data to holistically capture and illuminate the complex health status of patients. Its proprietary NOSIS dataset is one of the largest and fastest growing hybrid biomarker clinical data sets for sepsis care. The Sepsis ImmunoScore Diagnostics on the ImmunixPlatform has the potential to save thousands of lives and billions of dollars in healthcare spending annually. The Sepsis ImmunoScore is not yet approved for commercial use in The United States. More information is available at:

1 Buchman, Timothy G. PhD, MD, et al., Sepsis Among Medicare Beneficiaries: 1. The Burdens of Sepsis, 2012-2018 *, Critical Care: March 2020 – Volume 48 – Issue 3 – pp. 276-288 doi: 10.1097 / CCM.0000000000004224

2 Karakike, Eleni MD, et al., Coronavirus disease 2019 as a cause of virus sepsis, intensive care medicine: July 12, 2021 – Volume – edition – doi: 10.1097 / CCM.0000000000005195

View the original content to download multimedia:

SOURCE Prenosis

The above press release is courtesy of PRNewswire. The views, opinions, and statements contained in the press release are not endorsed by, nor do they necessarily reflect those of Gray Media Group, Inc.

Source link

Leave A Reply

Your email address will not be published.